Journal
ARTHRITIS CARE & RESEARCH
Volume 72, Issue 4, Pages 489-497Publisher
WILEY
DOI: 10.1002/acr.23879
Keywords
-
Categories
Funding
- MRC [MR/K006665/1, MR/P023576/2, G0902272] Funding Source: UKRI
- Wellcome Trust [107851/Z/15/Z] Funding Source: Wellcome Trust
- Medical Research Council [MR/P023576/2, MR/K006665/1, G0902272, MC_PC_13042] Funding Source: Medline
- Wellcome Trust [107851/Z/15/Z] Funding Source: Medline
Ask authors/readers for more resources
Glucocorticoids (GCs) are widely used to effectively treat inflammatory disease, but GCs have a number of recognized side effects. Patients and clinicians view these side effects differently, with clinicians most concerned with serious side effects such as osteoporosis and diabetes mellitus. Consequently, these side effects are well researched with clinical guidelines and recommendations. A side effect of particular concern to patients is weight gain, but this topic has not been well researched, and consequently clinicians find it difficult to provide patients with accurate information about the potential of weight gain. The aim of this review is to provide an overview of GC use specifically in rheumatic disease, patient views on GC therapy, and GC-induced weight gain. We will discuss the evidence, including the extent and the impact of weight gain on the patient, and highlight areas that warrant further investigation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available